Institutional Investors Reduce Stake Below 5% in Bolt Biotherapeutics
BOLT is trading near its 52-week low of $4.27 (14% above the low).
Summary
A group of institutional investors, including Nan Fung Group and Pivotal bioVenture Partners, reported selling approximately $194,521 worth of shares, reducing their collective beneficial ownership in Bolt Biotherapeutics below the 5% threshold.
Key Events · Ownership and Investor Activity · BOLT
-
Institutional Stake Reduced
A group of institutional investors, including Nan Fung Group and Pivotal bioVenture Partners, reported that their collective beneficial ownership in Bolt Biotherapeutics, Inc. has fallen below the 5% threshold as of February 26, 2026.
-
Significant Share Sales
The reporting persons sold a total of 40,669 shares between February 17, 2026, and February 26, 2026, for a total transaction value of approximately $194,521.
-
Ongoing Reduction
This filing follows a previous Schedule 13D/A on February 18, 2026, indicating a continued reduction in their holdings over the past week.
Analysis · BOLT · Life Sciences
A group of institutional investors, including Nan Fung Group and Pivotal bioVenture Partners, has significantly reduced its stake in Bolt Biotherapeutics, falling below the 5% beneficial ownership threshold. This action, involving the sale of over $194,000 worth of shares, signals a notable decrease in conviction or a strategic reallocation of capital by these major holders. For a micro-cap company, such a reduction by a significant institutional investor can be interpreted negatively by the market, potentially impacting investor sentiment and liquidity.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BOLT was trading at $4.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.9M. The 52-week trading range was $4.27 to $9.66. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.